Characterization of Thienylchalcones as hMAO‐B Inhibitors: Synthesis, Biochemistry and Molecular Dynamics Studies

[1]  B. Mathew,et al.  Monoamine oxidase inhibitory activity of methoxy-substituted chalcones. , 2017, International journal of biological macromolecules.

[2]  M. Soliman,et al.  Pharmacophore-Based 3D-QSAR Analysis of Thienyl Chalcones as a New Class of Human MAO-B Inhibitors: Investigation of Combined Quantum Chemical and Molecular Dynamics Approach. , 2017, The journal of physical chemistry. B.

[3]  B. Mathew,et al.  Monoamine Oxidase Inhibitory Activity: Methyl‐ versus Chlorochalcone Derivatives , 2016, ChemMedChem.

[4]  M. Soliman,et al.  Exploration of chlorinated thienyl chalcones: A new class of monoamine oxidase-B inhibitors. , 2016, International journal of biological macromolecules.

[5]  B. Mathew,et al.  Potent and Selective Monoamine Oxidase‐B Inhibitory Activity: Fluoro‐ vs. Trifluoromethyl‐4‐hydroxylated Chalcone Derivatives , 2016, Chemistry & biodiversity.

[6]  B. Mathew,et al.  Monoamine Oxidase Inhibitory Action of Chalcones: A Mini Review. , 2016, Central nervous system agents in medicinal chemistry.

[7]  B. Mathew,et al.  Monoamine Oxidase Inhibitors: Perspective Design for the Treatment of Depression and Neurological Disorders , 2016 .

[8]  S. L. Manju,et al.  Identification of Indole‐Based Chalcones: Discovery of a Potent, Selective, and Reversible Class of MAO‐B Inhibitors , 2016, Archiv der Pharmazie.

[9]  B. Mathew,et al.  Synthesis, Biochemistry, and Computational Studies of Brominated Thienyl Chalcones: A New Class of Reversible MAO‐B Inhibitors , 2016, ChemMedChem.

[10]  D. Edmondson,et al.  Design and synthesis of novel chalcones as potent selective monoamine oxidase-B inhibitors. , 2016, European journal of medicinal chemistry.

[11]  Sheetal,et al.  Recent developments on the structure–activity relationship studies of MAO inhibitors and their role in different neurological disorders , 2016 .

[12]  J. P. Petzer,et al.  Monoamine oxidase inhibitory activities of heterocyclic chalcones. , 2015, Bioorganic & medicinal chemistry letters.

[13]  B. Mathew,et al.  Development of Fluorinated Thienylchalcones as Monoamine Oxidase-B Inhibitors: Design, Synthesis, Biological Evaluation and Molecular Docking Studies , 2015 .

[14]  B. Mathew,et al.  Development of fluorinated methoxylated chalcones as selective monoamine oxidase-B inhibitors: Synthesis, biochemistry and molecular docking studies. , 2015, Bioorganic chemistry.

[15]  Dong Jin Kim,et al.  Synthesis of a series of unsaturated ketone derivatives as selective and reversible monoamine oxidase inhibitors. , 2015, Bioorganic & medicinal chemistry.

[16]  F. González-Nilo,et al.  Synthesis, Biological Evaluation, and Molecular Simulation of Chalcones and Aurones as Selective MAO‐B Inhibitors , 2015, Chemical biology & drug design.

[17]  S. Carradori,et al.  New Frontiers in Selective Human MAO-B Inhibitors. , 2015, Journal of medicinal chemistry.

[18]  Debarshi Kar Mahapatra,et al.  Chalcones and their therapeutic targets for the management of diabetes: structural and pharmacological perspectives. , 2015, European journal of medicinal chemistry.

[19]  J. Finberg.  Update on the pharmacology of selective inhibitors of MAO-A and MAO-B: focus on modulation of CNS monoamine neurotransmitter release. , 2014, Pharmacology & therapeutics.

[20]  J. C. Patterson,et al.  Molecular Dynamics Study of Zn(Aβ) and Zn(Aβ)2 , 2013, PloS one.

[21]  J. P. Petzer,et al.  Selected furanochalcones as inhibitors of monoamine oxidase. , 2013, Bioorganic & medicinal chemistry letters.

[22]  R. Ramsay.  Inhibitor design for monoamine oxidases. , 2013, Current pharmaceutical design.

[23]  M. Cordeiro,et al.  Discovery of MAO-B inhibitors - present status and future directions part I: oxygen heterocycles and analogs. , 2012, Mini reviews in medicinal chemistry.

[24]  D. Secci,et al.  Chalcones: a valid scaffold for monoamine oxidases inhibitors. , 2009, Journal of medicinal chemistry.

[25]  Jack J. Chen,et al.  Monoamine Oxidase‐B Inhibition in the Treatment of Parkinson's Disease , 2007, Pharmacotherapy.

[26]  C. Olanow.  Rationale for considering that propargylamines might be neuroprotective in Parkinson’s disease , 2006, Neurology.

[27]  Keith F. Tipton,et al.  The therapeutic potential of monoamine oxidase inhibitors , 2006, Nature Reviews Neuroscience.

[28]  J. Benito-León,et al.  Population-based case-control study of cognitive function in essential tremor , 2006, Neurology.

[29]  Andrea Mattevi,et al.  Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. , 2004, Journal of medicinal chemistry.

[30]  M. Sawada,et al.  Molecular mechanism of the relation of monoamine oxidase B and its inhibitors to Parkinson's disease: possible implications of glial cells. , 2006, Journal of neural transmission. Supplementum.

[31]  J. Shih,et al.  Monoamine oxidase: from genes to behavior. , 1999, Annual review of neuroscience.